Sort

Search

Search Bar
17/10/2023 Impact of functional dependency of elderly patients seen in Spanish emergency departments during the first wave of the COVID-19 pandemic on mortality at 30, 180 and 365 days depending on the diagnosis (COVID versus non-COVID)
Alonso, CF, Ferrer, MEF, García-Lamberechts, EJ, Mir, SA, Jiménez, S, Rodriguez, JJ, Salmerón, PP, Gil-Rodrigo, A, Llorens, P, Burillo-Putze, G, Pérez, FJM, Alquezar-Arbé, A, Gallardo, RR, Diez, MAB, Más, MT, López-Laguna, N, Soler, AC, Nespereira, EG, García, AG, Ezponda, P, Lorenzo, AM, Liarte, JVO, Martín, JMS, Puente, PH, Villalibre, AM, del Castillo, JG, Miró, O. Impact of functional dependency of elderly patients seen in Spanish emergency departments during the first wave of the COVID-19 pandemic on mortality at 30, 180 and 365 days depending on the diagnosis (COVID versus non-COVID). Revista Espanola de Salud Publica. 2023; 97DOI:. PMID:. IF:0.900(Q4/9D).
16/10/2023 New-onset heart failure in infants: when the aetiological diagnosis becomes a challenge
Esmel-Vilomara R., Riaza L., Dolader P., Sabaté-Rotés A., Rosés-Noguer F., Gran F.. New-onset heart failure in infants: when the aetiological diagnosis becomes a challenge. EUROPEAN JOURNAL OF PEDIATRICS. 2023; DOI:10.1007/s00431-023-05286-5. PMID:37843615. IF:3.000(Q1/2D).
16/10/2023 Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target
Roychowdhury T., Klarin D., Levin M.G., Spin J.M., Rhee Y.H., Deng A., Headley C.A., Tsao N.L., Gellatly C., Zuber V., Shen F., Hornsby W.E., Laursen I.H., Verma S.S., Locke A.E., Einarsson G., Thorleifsson G., Graham S.E., Dikilitas O., Pattee J.W., Judy R.L., Pauls-Verges F., Nielsen J.B., Wolford B.N., Brumpton B.M., Dilmé J., Peypoch O., Juscafresa L.C., Edwards T.L., Li D., Banasik K., Brunak S., Jacobsen R.L., Garcia-Barrio M.T., Zhang J., Rasmussen L.M., Lee R., Handa A., Wanhainen A., Mani K., Lindholt J.S., Obel L.M., Strauss E., Oszkinis G., Nelson C.P., Saxby K.L., van Herwaarden J.A., van der Laan S.W., van Setten J., Camacho M., Davis F.M., Wasikowski R., Tsoi L.C., Gudjonsson J.E., Eliason J.L., Coleman D.M., Henke P.K., Ganesh S.K., Chen Y.E., Guan W., Pankow J.S., Pankratz N., Pedersen O.B., Erikstrup C., Tang W., Hveem K., Gudbjartsson D., Gretarsdottir S., Thorsteinsdottir U., Holm H., Stefansson K., Ferreira M.A., Baras A., Kullo I.J., Ritchie M.D., Christensen A.H., Iversen K.K., Eldrup N., Sillesen H., Ostrowski S.R., Bundgaard H., Ullum H., Burgess S., Gill D., Gallagher K., Sabater-Lleal M., Dudbridge F., Samani N.J., Surakka I., Jones G.T., Bown M.J., Tsao P.S., Willer C.J., Damrauer S.M.. Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. NATURE GENETICS. 2023; 55(11)DOI:10.1038/s41588-023-01510-y. PMID:37845353. IF:31.800(Q1/1D).
15/10/2023 High-precision targeting and destruction of cancer-associated PDGFR-ß(+) stromal fibroblasts through self-assembling, protein-only nanoparticles.
Voltà-Durán E, Alba-Castellón L, Serna N, Casanova I, López-Laguna H, Gallardo A, Sánchez-Chardi A, Villaverde A, Unzueta U, Vázquez E, Mangues R. High-precision targeting and destruction of cancer-associated PDGFR-ß(+) stromal fibroblasts through self-assembling, protein-only nanoparticles.. Acta Biomaterialia. 2023; 170DOI:10.1016/j.actbio.2023.09.001. PMID:37683965. IF:9.400(Q1/1D).
15/10/2023 SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
Kulisevsky J, Esquivel A, Freire-Álvarez E, Gómez-Esteban JC, Legarda-Ramírez I, Mata-Álvarez-Santullano M. SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.. REVISTA DE NEUROLOGIA. 2023; 77(s02)DOI:10.33588/rn.77s02.2023217. PMID:37752685. IF:0.800(Q4/9D).
13/10/2023 Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib
Vallez-Valero L., Gasó-Gago I., Marcos-Fendian Á., Garrido-Alejos G., Riera-Magallón A., Plaza Diaz A., Martinez-Molina C., Mangues-Bafalluy M.A., Corominas H.. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib. CLINICAL RHEUMATOLOGY. 2023; 42(12)DOI:10.1007/s10067-023-06787-2. PMID:37831336. IF:2.900(Q2/4D).